PPT-Hepatology

Case Conference By Soheil Altafi MD 022415 Case 49 AAF seen in H epatology clinic 2011 PMHx PSC dx 2005 in BR lung dz unknown etiology PSHx bl tubal ligation cholecystectomy. naturecomclinicalpracticegasthe How to critically appraise an article Jane M Young and Michael J Solomon INTRODUCTION To practice evidencebased medicine clinicians need to apply the findings of scientific research to the circumstances of individual p Received: 1 June 2014 Accepted: 5 August 2014 Reprint or Correspondence ORIGINAL ARTICLE 34 Lymphangiectasia in dogs Gastroenterol Hepatol 2015;8(1):33-41 lymphoplasmacytic enteritis (LPE) (3, 4). Diagnosis and Management. Pippa. Newell, M.D.. Medical Director, Liver Cancer Program. Providence . Cancer Center, Portland. Hepatobiliary. Surgeon. The Oregon Clinic. philippa.newell@providence.org. immune escape . mutants. Anders Boyd, MPH, . PhD. Inserm UMR_S1136 . iPLESP. 3rd . International HIV/Viral Hepatitis Co-infection Meeting. Antiviral resistance mutants. What are the . selective pressures . N = 69. >. 18 years. Failure to SOF/VEL . or SOF/VEL + VOX . (LEPTON study). Any genotype. Compensated cirrhosis allowed. No HBV or HIV co-infection. Open-label. SOF/VEL: 400/100 mg FDC QD ; RBV: weight based in twice daily dose . in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. Design. Objective. SVR. 12. (HCV RNA < 25 IU/ml) in genotype 1. DCV 60 mg . qd. + . SOF 400 mg . qd. + RBV. DCV 60 mg . qd. + . SOF 400 mg . qd. + RBV. Not . randomised. Open-label. ALLY-1 Study: DCV + SOF + RBV for advanced liver disease and post-liver transplant recurrence. in genotypes 1 or 3, with or without cirrhosis. >. 18 years. Chronic HCV infection. Genotype 1 or 3. HCV RNA > 10 000 IU. /ml. Treatment-naïve . Cirrhosis assessed by liver biopsy or noninvasive tests. Randomisation. 1 : 1. 18-70 years. HCV genotype 1. Naïve or pre-treated. with IFN-based regimen. No cirrhosis. HCV RNA ≥ . 10.000 . IU. /ml. No prior therapy with PI. No HBV or HIV co-infection. OPTIMIST-1 Study: SMV SOF for genotype 1. About these slides. These slides provide highlights of new data presented at the International Liver Congress 2018. Please feel free to use, adapt, and share these slides for your own personal use; however, please acknowledge EASL as the source. Moderator. Kris V. Kowdley, MD . Director . Liver Institute Northwest . Clinical Professor. Elson S. Floyd College of Medicine. Washington State University. Seattle, Washington . Overview of Discussion. AutoantibodyandHumanLeukocyteAntigenProfiles inChildrenWithAutoimmuneLiverDiseaseand TheirFirst-DegreeRelatives
PengyunWang, jj HaibinSu,
JamesUnderhill,
LauraJ.Blackmore,
MariaSer Chair of the BSG Training Committee. The Shape of Gastroenterology Training. The many facets of gastroenterology. …. and don’t forget the rest of the body!. My own experience (how not to train a gastroenterologist). Iskren. . Kotzev. Medical University, Varna. Лечение на рефрактерни пациенти с автоимунни чернодробни болести. Primary . biliary. . cholangitis.